Rafael Beltran
Psychiatry · St Petersburg, FLNPI 1093807075
Payments from drug & device makers
Across 537 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Axsome Therapeutics, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$915
- Alkermes, Inc.$783
- plus $5K from 26 others
What the payments were for
- Food & beverage$12,74199%
- Education$1291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,869 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 76 | $58,227 |
| VraylarCariprazine Hcl | 16 | $34,280 |
| CaplytaLumateperone Tosylate | 15 | $25,119 |
| BelsomraSuvorexant | 27 | $11,840 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,251 |
| Aripiprazole | 56 | $3,146 |
| Lisdexamfetamine Dimesylate | 12 | $2,129 |
| Duloxetine Hcl | 108 | $1,994 |
| Olanzapine | 87 | $1,874 |
| Bupropion XlBupropion Hcl | 78 | $1,684 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 44 | $1,602 |
| Alprazolam | 217 | $1,517 |
| Lamotrigine | 113 | $1,407 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 24 | $1,354 |
| Escitalopram Oxalate | 126 | $1,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,245 | $62,47887 claims |
| AbbVieVraylar | $2,185 | $34,28016 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $915 | $25,11915 claims |
| Almatica Pharma LLCSertraline Hcl | $37 | $28439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in St Petersburg
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.